Form 4: Arcus Biosciences Director Receives Equity Grant

Director Andrew J. Perlman was granted 5,700 restricted stock units and 16,900 stock options by Arcus Biosciences.

Summary

• Director Andrew J. Perlman received an equity grant on June 11, 2026.
• The grant includes 5,700 restricted stock units (RSUs) valued at $0.
• The grant includes 16,900 stock options with an exercise price of $23.30.
• Following the transaction, the director's total beneficial ownership of common stock is 48,325 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The issuance of new equity results in minor dilution to existing shareholders.

Risks

• Potential for future dilution if stock options are exercised.

Future Outlook

The equity grants vest in full on June 11, 2027, or upon the next annual meeting of stockholders, or immediately in the event of a change in control.

Management Comments

• The grants are standard compensation for board service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of time-based vesting (one year) is consistent with standard industry practices for non-employee director compensation.
• The inclusion of change-in-control acceleration clauses is standard for executive and director equity agreements.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of equity grants on June 11, 2027.

Key Dates

Keywords

Arcus Biosciences, RCUS, Form 4, Insider Trading, Equity Compensation, Director Compensation